ArticleJournal of leukocyte biology2010
CD13 is dispensable for normal hematopoiesis and myeloid cell functions in the mouse.
Article in Journal of leukocyte biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 67 citations in OpenAlex.
- Article
- MyD88-mediated chimaeric antigen receptor macrophages suppress brain metastasis using target-specific phagocytosis.Nature biomedical engineering · 2026Article
- CD13 expression affects glioma patient survival and influences key functions of human glioblastoma cell lines in vitro.BMC cancer · 2024Article
- CD13 facilitates immune cell migration and aggravates acute injury but promotes chronic post-stroke recovery.Journal of neuroinflammation · 2023Article
- Soluble CD13 induces inflammatory arthritis by activating the bradykinin receptor B1.The Journal of clinical investigation · 2022Article
- CD13 orients the apical-basal polarity axis necessary for lumen formation.Nature communications · 2021Article
- CD13 is a critical regulator of cell-cell fusion in osteoclastogenesis.Scientific reports · 2021Article
- Coronavirus Receptors as Immune Modulators.Journal of immunology (Baltimore, Md. : 1950) · 2021Review
- Article
- CD13/Aminopeptidase N Is a Potential Therapeutic Target for Inflammatory Disorders.Journal of immunology (Baltimore, Md. : 1950) · 2020Review
- CD13 deficiency leads to increased oxidative stress and larger atherosclerotic lesions.Atherosclerosis · 2019Article
- Angiogenic and Arthritogenic Properties of the Soluble Form of CD13.Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- Resistance to coronavirus infection in amino peptidase N-deficient pigs.Transgenic research · 2019Article
- Micro-ribonucleic acid-155 is a direct target of Meis1, but not a driver in acute myeloid leukemia.Haematologica · 2018Article
- Immunofluorescence identifies distinct subsets of endothelial cells in the human liver.Scientific reports · 2017Article
- The Aminopeptidase CD13 Induces Homotypic Aggregation in Neutrophils and Impairs Collagen Invasion.PloS one · 2016Article
- CD13 mediates phagocytosis in human monocytic cells.Journal of leukocyte biology · 2015Article
- CD13 restricts TLR4 endocytic signal transduction in inflammation.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Molecular mechanisms regulating CD13-mediated adhesion.Immunology · 2014Article
- CD13 regulates anchorage and differentiation of the skeletal muscle satellite stem cell population in ischemic injury.Stem cells (Dayton, Ohio) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
The robust and consistent expression of the CD13 cell surface marker on very early as well as differentiated myeloid hematopoietic cells has prompted numerous investigations seeking to define roles for CD13 in myeloid cells. To address the function of myeloid CD13 directly, we created a CD13 null mouse and assessed the responses of purified primary macrophages or DCs from WT and CD13 null animals in cell assays and inflammatory disease models, where CD13 has been implicated previously. We find that mice lacking CD13 develop normally with normal hematopoietic profiles except for an increase in thymic but not peripheral T cell numbers. Moreover, in in vitro assays, CD13 appears to be largely dispensable for the aspects of phagocytosis, proliferation, and antigen presentation that we tested, although we observed a slight decrease in actin-independent erythrocyte uptake. However, in agreement with our published studies, we show that lack of monocytic CD13 completely ablates anti-CD13-dependent monocyte adhesion to WT endothelial cells. In vivo assessment of four inflammatory disease models showed that lack of CD13 has little effect on disease onset or progression. Nominal alterations in gene expression levels between CD13 WT and null macrophages argue against compensatory mechanisms. Therefore, although CD13 is highly expressed on myeloid cells and is a reliable marker of the myeloid lineage of normal and leukemic cells, it is not a critical regulator of hematopoietic development, hemostasis, or myeloid cell function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.